Huang et al. demonstrated that different EGFR-TKIs (erlotinib and afatinib) plus bevacizumab provided similar clinical efficacy for treatment of advanced-stage EGFR-mutant lung adenocarcinoma [16]. This evidence concerns the gene EGFR and lung adenocarcinoma.